Antitumor effector cells in spleens of tumor-bearing mice given ubenimexwere investigated. The administration of ubenimex, starting 7 days after the tumor inoculation, was effective in inhibiting growth of IMCcarcinoma. Spleen cells taken from these mice showed a marked suppression of the tumor growth by the Winnassay. The antitumor activity of spleen cells was reduced by treatment to remove T cells or NKcells, whereas spleen cell preparations enriched for T cells showed the strongest antitumor activity. Moreover, NK activity against YAC-1cells was found in the spleen. These results indicate that the administration of ubenimex to IMCcarcinoma-bearing mice generates cytotoxic T cells and NKcells in the spleen.
Wehave previously reported the immunomodulatory effect and antitumor activity of ubenimex in experimental animals1~4). These results indicate that the antitumor activity of ubenimex is manifested through activation of host defense mechanisms. Amongantitumor effector cells, NKcells5) and macrophages6) were activated by ubenimex in vitro. However, the effector cells activated by ubenimex in a tumor-bearing host are not known, although it was shown that NKactivity was increased in ubenimex-treated rats having carcinogen-induced stomach cancer4). Thus, we examined the effector cells in tumor-bearing mice given ubenimex.
Materials and Methods

Mice
CDFXmice (6~8 weeks old, female) were purchased from Charles River Japan Inc. and were maintained under specific pathogen-free conditions at 23±2°C and 55±5%humidity. They were employed for experiments at 8 to 12 weeks of age.
Ubenimex
Ubenimex was prepared and supplied by Nippon Kayaku Co., Ltd. and dissolved in saline or culture medium.
Tumor and Cell Line
IMCcarcinoma was maintained in CDF*mice by weekly intraperitoneal injection. YAC-1cells were maintained in RPMI1640 containing 10% fetal calf serum.
Antitumor Activity and Tumor Neutralization Assay CDF2mice were inoculated subcutaneously with 2x lO6 cells in 0.1 ml of saline and given an oral dose of ubenimex, starting 7 days after the tumor inoculation, every other day for a total of 10 MAY 1987 doses. Antitumor activity was determined by measuring tumor size (mm2) at weekly intervals and by weighing the tumor 30 days after tumor inoculation.
Antitumor activity of ubenimex in immuno-deficient mice was also tested. X-Ray-irradiated mice were prepared as follows : CDFXmice were irradiated with 200 rad of X-ray daily for 7 days before tumor inoculation. Mice with impaired NKactivity were prepared by intraperitoneal injection of anti-asialo GM1serum. CDFi mice were injected intraperitoneally with 5 [A of anti-asialo GM1 serum, 2 days before, and 4, 10 and 16 days after tumor inoculation. These mice were inoculated subcutaneously with 2 x 106 IMC carcinoma cells and, from 7 days thereafter, given 5 mg/kg of ubenimexevery other day for a total of 10 times. Tumorneutralization assay was performed by the Winn assay7). Spleen cells were taken from untreated mice or from those treated with ubenimex 30 days after the tumor inoculation. To destroy T cells or NKcells, spleen cells were incubated with diluted anti-thy 1.2 serum (Cederlane Laboratories, Ltd., Ontario, Canada) or a diluted anti-asialo GM1serum (Wako Chemicals Co., Ltd., Tokyo), respectively, at 4°C for 30 minutes, after which complement was added and incubation continued at 37°C for 60 minutes. According to the method reported previously8), spleen cells were incubated in a nylon wool column (Wako Chemicals Co., Ltd., Tokyo) at 37°C for 60 minutes, and non-adherent cells (nylon wool column-passed cells) were used as a T cell-enriched population. These cells were mixed with 1 x 106 IMCcarcinoma cells at a ratio of 80 : 1 and the mixture in 0.2 ml was inoculated subcutaneously into mice. Thirty days thereafter, antitumor activity of each cell population was determined by measuring tumor weight.
NKActivity The NKactivity of spleen cells taken from mice given ubenimex 30 days after tumor inoculation was determined against YAC-1cells according to the method described before8). YAC-1cells were labeled with 51Cr (New England Nuclear, Boston, Mass., U.S.A.), and 2 X 105 cells/ml were incubated with effector cells at ratios of 100 : 1 for 4 hours. After incubation the supernatant was collected and 51Cr radioactivity was counted in a gammacounter (Aloka Co., Ltd., Tokyo). The maximum counts in target cells were determined after disruption by freezing and thawing. The mean percentage of specific cytotoxicity was calculated as follows :
Maximum count -Spontaneous count xlOO
Results and Discussion
As shown in Fig. 1 , the administration of ubenimex resulted in marked antitumor activity against IMCcarcinoma. Wehave previously shown that the antitumor activity of ubenimex against murine transplantable tumors such as IMCcarcinoma0 and leukemia C14982) is dependent on dosage and time of administration during the period of tumor growth in mice. In this case, the oral administration of ubenimex at 5 mg/kg starting 7 days after the tumor inoculation was effective in inhibiting growth of the tumor.
Thirty days after tumor inoculation into untreated mice or into those subsequently given ubenimex, spleen cells were taken and their antitumor activity was determined by the Winnassay. As shown in Table 1 , spleen cells taken from mice given ubenimex showed a marked suppression of the tumor growth. On the other hand, spleen cells treated with anti-thy 1.2 serum or anti-asialo GM1serum and complement had little antitumor activity. The spleen cells which had passed through a nylon wool column showed the strongest antitumor activity. All mice inoculated with a mixture of tumor cells and nylon wool column-passed cells were tumor-free. These results indicate that the administration of ubenimex to IMCcarcinoma-bearing mice activates cytotoxic T cells and NKcells in the spleen.
NKactivity of spleen cells taken from mice given ubenimex was determined against YAC-1cells. As shown in Table 2 , the administration of ubenimex at 5.0mg/kg showedthe strongest antitumor effect and resulted in the highest NK activity. The antitumor effect coincided with the NKactivity of the spleen cells. As reported previously^, ubenimex administration inhibited development of MNNG-induced stomach cancer in rats and their NK activity was increased. However, ubenimex alone neither induces interferons nor enhances NKactivity in normal mice, although it augments production of interferons in BCG-sensitized mice*. It was reported that ubenimex induced production of interleukin 1 (IL-1) by macrophages9) and enhanced production of interleukin 2 (IL-2) in spleen cell cultures stimulated with concanavalin A (Con A)9'10) or allogeneic cells11}. Thus, it can be considered that the high NK activity induced in tumorbearing hosts by ubenimex treatment may be due to enhanced production of cytokines, including IL-2, which participate to activate NK cells or to inhibit suppressor factors12) of NK activity present in tumor-bearing mice. As described above, the effect of ubenimex of NK activity also depends on its dosage level as well as the antitumor activity. It may be due to effects of ubenimexon membrane-associated events of macrophages and/or lyniphocytes13). The antitumor effect of ubenimex in X-ray-irradiated and in anti-asialo GM1serum-treated mice was examined, and the results were shown in Table 3 . In normal mice, ubenimex showed a marked antitumor effect against IMCcarcinoma, whereas the effect was not observed in either kind of im-T Okura, A.; M. Ishizuka & H. Umezawa: in preparation. a Mice were irradiated with 200rad of X-ray daily for 7 days before tumor inoculation. b Mice were injected with 5^I/mouse of anti-asialo GM1serum, 2 days before and 4, 10 and 16 days after tumor inoculation.
c Ubenimex(5 mg/kg, po) was given a total of 10 times every other day starting 7 days after tumor inoculation.
d Tumorweight was measured 30 days after tumor inoculation. muno-deficient mouse. This result indicates that the antitumor effect of ubenimex is a host-mediated event and that X-ray-sensitive cells and asialo GM1-bearing cells such as NKcells are essential for the antitumor effect in mice.
The results shown in this report indicate that ubenimex treatment activates cytotoxic T cells and NKcells in tumor-bearing mice. These cells may be generated through ubenimex-activated cytokine production and/or inhibition of suppressors present in the tumor-bearing host.
